Literature DB >> 20371032

Major depressive disorder treatment guidelines in Japan.

Teruhiko Higuchi1.   

Abstract

Japanese treatment guidelines, consensus guidelines, and treatment algorithms for managing patients with major depressive disorder (MDD) have been developed and/or updated in the past decade. The treatment guidelines, which are evidence-based, are the most detailed of the 3 types of guidance; they describe how to establish a treatment plan, treatment methods, and special problems such as intractable depression and suicide. The Japanese consensus guidelines were compiled from the results of a survey about treatment choices in MDD that was sent to members of the Japanese Society of Psychiatry and Neurology. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors were the most common first-line treatments, followed by tricyclic antidepressants and tetracyclic antidepressants. The consensus guidelines are not evidence-based but are practical and easy to use. The Japanese treatment algorithm for MDD is a flowchart created in conjunction with the International Psychopharmacology Algorithm Project. The flowchart shows steps in treatment both for patients who respond to initial treatment and for those who need several trials of treatment. These 3 forms of guidance for managing patients with MDD in Japan are reviewed.

Entities:  

Mesh:

Year:  2010        PMID: 20371032     DOI: 10.4088/JCP.9058se1c.05gry

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder.

Authors:  Ashwin A Patkar; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

2.  Melancholic and reactive depression: a reappraisal of old categories.

Authors:  Jin Mizushima; Hitoshi Sakurai; Yuya Mizuno; Masaki Shinfuku; Hideaki Tani; Kadunari Yoshida; Chisa Ozawa; Asako Serizawa; Natsuko Kodashiro; Shinya Koide; Atsumi Minamisawa; Eisaku Mutsumoto; Nobuhiro Nagai; Sachiko Noda; Genichiro Tachino; Tatsuichiro Takahashi; Hiroyoshi Takeuchi; Toshiaki Kikuchi; Hiroyuki Uchida; Koichiro Watanabe; Hiroki Kocha; Masaru Mimura
Journal:  BMC Psychiatry       Date:  2013-11-16       Impact factor: 3.630

3.  Evidence-based treatment for depressive disorder.

Authors:  Chi-Un Pae
Journal:  Psychiatry Investig       Date:  2015-03-18       Impact factor: 2.505

4.  Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.

Authors:  Takeshi Inoue; Kiyofumi Sasai; Tadayuki Kitagawa; Akira Nishimura; Isao Inada
Journal:  Psychiatry Clin Neurosci       Date:  2019-12-18       Impact factor: 5.188

Review 5.  Recent Studies on Anti-Depressant Bioactive Substances in Selected Species from the Genera Hemerocallis and Gladiolus: A Systematic Review.

Authors:  Renata Matraszek-Gawron; Mirosława Chwil; Paulina Terlecka; Michał M Skoczylas
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-25

6.  A neural network approach to optimising treatments for depression using data from specialist and community psychiatric services in Australia, New Zealand and Japan.

Authors:  Aidan Cousins; Lucas Nakano; Emma Schofield; Rasa Kabaila
Journal:  Neural Comput Appl       Date:  2022-01-13       Impact factor: 5.606

7.  Treatment-resistant depression in primary care across Canada.

Authors:  Sakina J Rizvi; Etienne Grima; Mary Tan; Susan Rotzinger; Peter Lin; Roger S Mcintyre; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2014-07       Impact factor: 4.356

8.  Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study.

Authors:  Young Sup Woo; Roger S McIntyre; Jung-Bum Kim; Min-Soo Lee; Jae-Min Kim; Hyeon Woo Yim; Tae-Youn Jun
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-11-30       Impact factor: 2.582

9.  Work functioning impairment in the course of pharmacotherapy treatment for depression.

Authors:  Tomohisa Nagata; Yoshihisa Fujino; Makoto Ohtani; Kenji Fujimoto; Masako Nagata; Shigeyuki Kajiki; Makoto Okawara; Koji Mori
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.